Is 7OH Legal in Canada? Regulatory Status Explained (2026)

“Is 7OH legal in Canada?” is one of the most common questions we hear, and it deserves a clear, thorough answer. The problem with most information available online is that it either oversimplifies (just saying “yes, it’s legal”) or buries the real answer under vague language that leaves you more confused than when you started.

This article gives you the full picture. We walk through the specific Canadian laws that apply, explain how Health Canada views 7-hydroxymitragynine, cover the major U.S. regulatory shifts from 2025 and what they might mean for Canada, and spell out how 7OH products are legally sold in this country right now.

If you are new to 7OH entirely and want to understand the compound before diving into the legal side, start with our complete guide to 7-hydroxymitragynine.

The Short Answer

As of 2026, 7-hydroxymitragynine (7OH) is not listed as a controlled substance in Canada. It does not appear on any schedule of the Controlled Drugs and Substances Act (CDSA). Possessing or purchasing 7OH is not prohibited under Canadian controlled substance legislation.

However, Health Canada has not approved 7OH or any kratom-derived product for human consumption, therapeutic use, or sale as a natural health product.

This creates a regulatory space where 7OH can be legally purchased and sold in Canada, but only under specific conditions. Products must be labeled and marketed appropriately, typically for research, laboratory, or analytical purposes rather than for human consumption.

That is the short version. The rest of this article explains the “why” behind each part of that answer.

Understanding Canada’s Regulatory Framework

To understand where 7OH fits legally in Canada, you need to understand two pieces of federal legislation that govern different aspects of substance regulation.

The Controlled Drugs and Substances Act (CDSA) determines whether a substance is “controlled,” meaning its possession, production, sale, or import is restricted or prohibited. If a compound appears on one of the CDSA schedules (Schedule I through VI), handling it without authorization is a criminal offense.

The Food and Drugs Act (FDA) and its regulations govern products sold for human consumption, therapeutic use, or as natural health products. Health Canada administers this legislation and decides whether a product can be legally marketed for health purposes.

These two laws operate independently. A substance can be uncontrolled under the CDSA but still unauthorized for sale as a consumable product under the Food and Drugs Act. This is exactly the situation with 7OH and kratom in Canada.

7OH and the Controlled Drugs and Substances Act

The CDSA is the law that matters most when people ask “is 7OH legal in Canada?” because it determines whether possessing or purchasing the compound is a criminal matter.

7-Hydroxymitragynine does not appear on any CDSA schedule. Neither does its parent compound, mitragynine. Neither does kratom (Mitragyna speciosa) itself.

This means that under Canadian controlled substance law, 7OH is not a prohibited or restricted substance. You will not face criminal penalties for possessing it, purchasing it, or importing it for personal or research use. This stands in contrast to compounds like psilocybin (Schedule III) or cannabis (which was Schedule II before legalization), where possession without authorization carried criminal consequences.

The CDSA schedules are reviewed and updated by the federal government. If 7OH were ever added to a CDSA schedule, the legal situation would change. As of early 2026, there has been no public indication from the Canadian government that scheduling 7OH is being considered. But the U.S. regulatory developments discussed later in this article are worth monitoring because Canadian scheduling decisions have historically been influenced by actions taken in other jurisdictions.

Health Canada’s Position on Kratom and 7OH

While the CDSA does not restrict 7OH, Health Canada’s regulatory authority adds an important layer.

Health Canada has not approved kratom or any of its alkaloids (including 7-hydroxymitragynine and mitragynine) for sale as a natural health product, dietary supplement, food, or therapeutic agent. To be sold legally for human consumption in Canada, a product generally needs a Natural Product Number (NPN), a Drug Identification Number (DIN), or another form of regulatory authorization. Kratom and 7OH have none of these.

Health Canada has taken enforcement actions against companies selling kratom products marketed for human consumption. The agency has issued seizure orders, particularly targeting products making health claims or products labeled in ways that suggest they are intended for ingestion.

The agency’s position is consistent: kratom-derived products have not been evaluated for safety and efficacy under Canadian regulatory standards, and selling them for consumption is not authorized.

What does this mean practically? It means vendors who sell 7OH in Canada need to be careful about how they label and market their products. Selling 7OH for “research use,” “laboratory analysis,” or “analytical reference” is permissible. Selling it as a supplement, health product, or consumable intended for ingestion is not compliant with Health Canada’s framework.

The Food and Drugs Act: Why Labeling Matters

The Food and Drugs Act gives Health Canada authority to regulate any product marketed for a therapeutic purpose or intended for human consumption. If a product’s labeling, advertising, or marketing implies that it is meant to be consumed or that it provides health benefits, it falls under this regulatory umbrella.

This is why you will see 7OH products in Canada labeled with statements like “for research purposes only” or “not for human consumption.” These are not arbitrary disclaimers. They reflect a legal requirement. Without them, the product could be classified as an unauthorized drug or natural health product, which would make its sale non-compliant.

For buyers, this labeling standard is actually a useful quality signal. Companies that label their products properly are demonstrating that they understand the regulatory environment and are operating within it. Companies that market 7OH tablets as supplements, wellness products, or consumer goods without appropriate disclaimers are either uninformed about or indifferent to Canadian regulations.

When you order 7OH online in Canada, proper labeling is one of the first things to check.

What Changed in the United States in 2025

While this article focuses on Canadian law, the U.S. regulatory landscape shifted significantly in 2025 and these changes are relevant to Canadian buyers and researchers.

The HHS Schedule I Recommendation. In early 2025, the U.S. Department of Health and Human Services (HHS) formally recommended that 7-hydroxymitragynine be placed in Schedule I of the Controlled Substances Act. This recommendation was based on the FDA’s assessment that 7OH has potent mu-opioid receptor agonist properties and poses public health concerns, particularly in concentrated, semisynthetic product formulations.

FDA Warning Letters. In July 2025, the FDA issued warning letters to vendors marketing concentrated 7OH products. The letters targeted products making therapeutic claims and products sold in forms (sublingual tablets, nasal sprays) designed to maximize bioavailability.

FDA Seizure Actions. The FDA also conducted seizures of 7OH products from commercial vendors, framing these actions as protecting consumers from unapproved opioid products.

The DEA’s Role. As of early 2026, the U.S. Drug Enforcement Administration (DEA) has not finalized scheduling of 7-hydroxymitragynine. The recommendation from HHS is under review, and a formal rulemaking process (including a public comment period) would be required before scheduling takes effect.

The Key Distinction. The U.S. regulatory actions specifically target semisynthetic, concentrated 7OH products, not natural kratom leaf. The FDA and HHS have emphasized that natural kratom contains only trace amounts of 7OH (less than 2% of total alkaloid content), and their concern centers on manufactured products containing 7OH at concentrations far above natural levels.

Could U.S. Regulations Affect Canada?

This is the question that comes up frequently in conversations about 7OH in Canada, and it is worth addressing directly.

There is no automatic mechanism by which a U.S. scheduling decision applies in Canada. The CDSA and the U.S. Controlled Substances Act are separate legal frameworks governed by different authorities. The DEA scheduling 7OH in the United States would not, by itself, change the legal status of 7OH in Canada.

That said, Canadian regulatory decisions do not happen in a vacuum. Historically, when the U.S. moves to schedule a substance, it creates regulatory momentum that other countries pay attention to. Health Canada monitors international developments, and a U.S. scheduling action could prompt a Canadian review.

Several factors would influence whether Canada follows the U.S. path. These include whether domestic health concerns about 7OH emerge in Canadian data, whether the WHO Expert Committee on Drug Dependence issues a recommendation (their pre-review of kratom alkaloids has already been completed), and whether public health incidents involving 7OH products occur in Canada.

For Canadian researchers and buyers, the practical takeaway is this: 7OH is legal in Canada today, and there is no immediate indication that this will change. But the U.S. situation is worth monitoring, and it would be prudent to stay current with Health Canada communications and CDSA schedule updates.

How 7OH Is Legally Sold in Canada

Given the regulatory framework described above, 7OH products in Canada occupy a defined legal space. Here is how compliant sales work.

Product labeling. Products are labeled for research, laboratory, or analytical use. They carry statements indicating they are not intended for human consumption. This labeling aligns with Health Canada’s requirement that unauthorized products not be marketed as consumables.

No health claims. Compliant vendors do not make therapeutic claims about their products. You will not see statements about pain relief, mood enhancement, or any other health benefit on properly labeled 7OH products in Canada.

Age restrictions. Many Canadian vendors require purchasers to be 19 years of age or older, consistent with provincial age-of-majority requirements in most provinces.

Domestic fulfillment. Products shipped within Canada avoid the Canada Border Services Agency (CBSA) import scrutiny that can apply to international shipments of kratom-related products. This is one of the practical advantages of buying from a Canadian supplier.

Batch documentation. Reputable vendors provide batch-specific documentation, including testing data that confirms compound identity and purity. This serves both regulatory compliance and customer quality assurance purposes.

If you want to browse what compliant 7OH products look like in practice, visit our shop. For more detail on what to look for when ordering, see our guide to buying 7OH in Canada.

Province-by-Province Considerations

Canada’s federal system means that provinces can, in some cases, layer additional requirements on top of federal law. For 7OH specifically, no province has enacted legislation that specifically targets 7-hydroxymitragynine or kratom alkaloids.

That said, provinces vary in how actively their health authorities monitor and enforce rules around products in this regulatory grey zone.

British Columbia has taken a relatively hands-off approach. The BC Poison Centre tracked kratom-related calls between 2012 and 2019, but no provincial legislation restricts 7OH sales.

Ontario has seen some enforcement activity around retailers marketing kratom products for consumption, but this reflects federal Food and Drugs Act enforcement rather than province-specific legislation.

Quebec has a history of stricter enforcement on health product regulations generally. Vendors operating in Quebec should be particularly careful about product labeling and marketing language.

Alberta, Saskatchewan, Manitoba, and the Maritime provinces have not enacted province-specific restrictions on kratom or 7OH products.

The bottom line: your location within Canada does not currently change the fundamental legal analysis. 7OH is not controlled federally, and no province has independently scheduled it. But enforcement intensity around labeling and marketing compliance can vary, so vendors should ensure their practices are clean regardless of where they ship.

International Regulatory Comparison

Understanding how other countries handle 7OH helps put Canada’s approach in context.

Australia classifies 7-hydroxymitragynine as a Schedule 9 prohibited substance. Possession, sale, and import are illegal.

United Kingdom regulates kratom under the Psychoactive Substances Act 2016, which broadly restricts psychoactive substances not already covered by other legislation.

Denmark, Poland, Romania, and several other European countries have banned kratom and its alkaloids outright.

Thailand banned kratom for decades but reversed course in 2021, decriminalizing and then legalizing kratom for traditional use.

United States maintains a patchwork approach. At the federal level, neither kratom nor 7OH is scheduled (as of early 2026), though the HHS recommendation could change this. At the state level, several states have banned kratom or enacted the Kratom Consumer Protection Act to regulate quality standards.

Canada’s position is closer to the U.S. approach than to Australia or Europe. The compound is not controlled, but it is not approved for consumption. This middle-ground approach gives researchers and buyers access while maintaining regulatory guardrails through Health Canada’s food and drug authority.

What Could Change and How to Stay Informed

Regulatory landscapes are not static. Several scenarios could alter 7OH’s legal status in Canada.

CDSA scheduling. If the federal government adds 7-hydroxymitragynine to a CDSA schedule, possession and sale would become criminal matters. This is the most impactful change that could occur, and currently the least likely in the near term.

Health Canada enforcement expansion. Even without CDSA scheduling, Health Canada could increase enforcement against 7OH products specifically, particularly if products marketed for consumption gain visibility.

WHO ECDD recommendation. The WHO Expert Committee on Drug Dependence has already conducted a pre-review of kratom alkaloids. A full review and recommendation could influence both Canadian and international regulatory decisions.

Provincial action. Individual provinces could theoretically restrict 7OH products through health product or consumer protection regulations, though none have done so to date.

To stay current, monitor these sources:

The CDSA schedules are published by the Department of Justice Canada and available on the federal laws website. Health Canada’s drug and health product advisories are published on canada.ca. The WHO ECDD publishes meeting reports and substance reviews on their website. For a quick reference on common questions, visit our FAQ page.

Frequently Asked Questions

Is 7OH legal in Canada?

Yes, as of 2026. 7-Hydroxymitragynine is not listed as a controlled substance under Canada’s Controlled Drugs and Substances Act. It can be legally purchased and possessed. However, Health Canada has not approved 7OH for human consumption or therapeutic use, so products must be labeled accordingly.

Is 7OH the same as kratom legally?

From a Canadian regulatory perspective, 7OH and kratom leaf occupy the same general space: neither is controlled under the CDSA, and neither is approved for consumption by Health Canada. However, the distinction between natural kratom (which contains trace 7OH) and concentrated, semisynthetic 7OH products is becoming increasingly important in regulatory discussions, particularly following U.S. enforcement actions in 2025.

Can I buy 7OH in Canada without a license?

Yes. Because 7OH is not a controlled substance in Canada, you do not need a special license to purchase it. Products labeled for research or analytical use can be bought by individuals and institutions. For details on sourcing, see our guide to ordering 7OH online in Canada.

Will 7OH be banned in Canada?

There is no public indication that 7OH is being considered for scheduling in Canada as of early 2026. However, the U.S. HHS recommendation to schedule 7OH and the FDA’s enforcement actions could influence future Canadian regulatory discussions. Monitoring official sources is advisable.

Is it legal to import 7OH into Canada?

7OH is not listed under the CDSA, so importing it is not prohibited under controlled substance law. However, the Canada Border Services Agency (CBSA) monitors shipments of kratom-related products, and items that appear to be marketed for consumption may be subject to scrutiny under the Food and Drugs Act. Buying from a domestic Canadian supplier avoids this issue entirely.

Where can I buy 7OH legally in Canada?

From Canadian suppliers that label their products for research or laboratory use and do not make health claims. Our online store carries research-grade 7OH tablets shipped from within Canada. For local sourcing options, see our 7OH near me guide.

What is the difference between the CDSA and the Food and Drugs Act?

The CDSA determines whether a substance is “controlled” (making possession, sale, or production a criminal offense). The Food and Drugs Act governs products marketed for consumption or therapeutic use, requiring authorization from Health Canada before a product can be sold for those purposes. A substance can be legal under the CDSA but still unauthorized for sale as a consumable under the Food and Drugs Act. This is the case with 7OH.

Disclaimer

This article is provided for educational and informational purposes only. It does not constitute legal advice of any kind.

While we have made every effort to present accurate information based on our understanding of current Canadian legislation and regulatory guidance, laws and regulations can change. Nothing in this article should be treated as a substitute for professional legal counsel.

All products sold by 7OH Lab are intended for research and laboratory use only. They are not for human consumption, internal use, or medical applications.

Individuals and institutions should consult official Canadian sources, including the CDSA schedules published by the Department of Justice Canada and communications from Health Canada, for the most current regulatory information.